Perspective Therapeutics’ VMT-α-NET Protocols Presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium
SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023.
- SEATTLE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society (NANETS) 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023.
- Enrollment for this study is expected to commence in the first quarter of 2024.
- “There are currently no approved targeted radiopharmaceuticals for NETs patients outside of the gastroenteropancreatic indication,” said Chief Executive Officer Thijs Spoor of Perspective Therapeutics.
- “These clinical studies are evaluating [212Pb]VMT-alpha-NET in a wide range of neuroendocrine tumors, where the unmet need is greatest.”